Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed

AIDS

Volumn 29, Issue 9, 2015, Pages 1053-1060

  Kuhn, Louise ^a,b   Schramm, Diana B ^c   Shiau, Stephanie ^a,b   Strehlau, Renate ^d   Pinillos, Francoise ^d   Technau, Karl ^d   Coovadia, Ashraf ^d   Abrams, Elaine J ^b   Puren, Adrian ^c   Tiemessen, Caroline T ^c  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b National Institute for Communicable Diseases ^*  (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Child diagnosis; Early infant diagnosis; HIV antibody; Low resource setting; Paediatric management; Paediatric treatment

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD DISEASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ELISA; HIV ELISA KIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AFRICA; VIRUS LOAD; AGE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; INFANT; PRESCHOOL CHILD; PROCEDURES;

AGE FACTORS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; INFANT; MALE; SOUTH AFRICA;

EID: 84988723110     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000677     Document Type: Article

References (24)

1. Gutierrez M, Ludwig DA, Khan SS, Chaparro AA, Rivera DM, Cotter AM, et al. Has highly active antiretroviral therapy increased the time to seroreversion in HIV exposed but uninfected children? Clin Infect Dis 2012; 55:1255-1261.
2. Creek TL, Sherman GG, Nkengasong J, Lu L, Finkbeiner T, Fowler MG, et al. Infant human immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country experiences. Am J Obstet Gynecol 2007; 197:S64-S71.
3. Desai N, Mathur M, Abu-Lawi K. HIV-1 seronegativity in a child with proved perinatal HIV infection on HAART. Sex Transm Infect 2005; 81:377-379.
4. Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenson M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000; 74:6984-6991.
5. Van der Linden D, Hainaut M, Goetghebuer T, Haelterman E, Schmitz V, Maes P, et al. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J 2007; 26:359-361.
6. Zanchetta M, Anselmi A, Vendrame D, Rampon O, Giaquinto C, Mazza A, et al. Early therapy in HIV-1-infected children: Effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther 2008; 13:47-55.
7. Hainaut M, Peltier CA, Gerard M, Marissens D, Zissis G, Levy J. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr 2000; 159:778-782.
8. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M Jr, Chun TW, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-1835.
9. Bitnun A, Samson L, Chun TW, Kakkar F, Brophy J, Murray D, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4R T cells carrying HIV in peripheral blood. Clin Infect Dis 2014; 59:1012-1019.
10. Butler KM, Gavin P, Coughlan S, Rochford A, Donagh SM, Cunningham O, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr Infect Dis J 2014.
11. Giacomet V, Trabattoni D, Zanchetta N, Biasin M, Gismondo M, Clerici M, et al. No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet 2014; 384:1320.
12. Garcia-Prats AJ, Draper HR, Sanders JE, Agrawal AK, Mohapi EQ, Schutze GE. False-negative post18-month confirmatory HIV tests in HIV DNA PCR-positive children: A retrospective analysis. AIDS 2012; 26:1927-1934.
13. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease- inhibitor-based regimen: long-Term follow-up of a randomised, open-label trial. Lancet Infect Dis 2012; 12:521-530.
14. Claassen M, van Zyl GU, Korsman SN, Smit L, Cotton MF, Preiser W. Pitfalls with rapid HIV antibody testing in HIVinfected children in the Western Cape, South Africa. J Clin Virol 2006; 37:68-71.
15. Merchant M, Wright M, Kabat W, Yogev R. Long-Term highly suppressed HIV-infected children and adolescents with negative rapid HIV tests due to significant antibody loss. J Clin Virol 2014; 59:172-176.
16. Payne H, Mkhize N, Morris L, Otwombe K, Panchia R, Violari A, et al. Routine antibody tests have no place in determining HIV status after early ART: Evidence from CHER [Abstract 922]. Conference on Retroviruses and Opportunistic Infections (CROI); 3-6 March 2014; Boston, MA.
17. Persaud D, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Ellis A, et al. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 2014; 168:1138-1146.
18. Luzuriaga K, Tabak B, Garber M, Chen YH, Ziemniak C, McManus MM, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1- infected children who received early treatment. J Infect Dis 2014; 210:1529-1538.
19. Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, et al. Dynamics of the resting CD4(R) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012; 26:1483-1490.
20. Ananworanich J, Puthanakit T, Suntarattiwong P, Chokephaibulkit K, Kerr SJ, Fromentin R, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 2014; 28:1015-1020.
21. Rainwater-Lovett K, Luzuriaga K, Persaud D. Very early combination antiretroviral therapy in infants: prospects for cure. Curr Opin HIV AIDS 2014.
22. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868-873.
23. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006; 42:700-708.
24. Tobin NH, Aldrovandi GM. Are infants unique in their ability to be 'functionally cured' of HIV-1? Curr HIV/AIDS Rep 2014; 11:1-10.